After obtaining a PhD in Paris in 1996 on the characterisation of novel neutrophil elastase inhibitors in COPD models, Gus pursued a post-doc in Cambridge where he characterised novel metalloproteinases with potential therapeutic applications for arthritis. In 1999, he joined GSK and led a team of assay scientists. In 2006 he transitioned to GSK’s Respiratory Therapy Area where he led multiple projects, and he now applies his experience gained on Respiratory projects to novel targets for various immune-related indications. Gus has deep expertise in molecular pharmacology and is experienced working with various immune cells, having authored over 50 publications and patents.

In addition to being a Biochemical Society Trustee and chairing the Society’s Industry Advisory Panel, Gus is also an Industry advisor to the EU-Openscreen consortium and a GSK scientific fellow, who enjoys mentoring the next generation of scientists.